PMID- 11013371
OWN - NLM
STAT- MEDLINE
DCOM- 20001017
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 89
IP  - 7
DP  - 2000 Oct 1
TI  - The clinical value of serum concentrations of cancer antigen 125 in patients with 
      primary fallopian tube carcinoma: a multicenter study.
PG  - 1555-60
AB  - BACKGROUND: Primary fallopian tube carcinoma (PFTC) is a rare disease, and data 
      on the serum concentration of tumor marker cancer antigen 125 (CA 125) in 
      patients with this disease are sparse. The authors assessed the clinical value of 
      the serum concentration of CA 125 as a prognostic and monitoring marker in 
      patients with surgically treated PFTC. METHODS: In a multicenter study, the 
      concentration of CA 125 was measured in 406 serum samples from 53 patients with 
      PFTC. The results were correlated with clinical data. RESULTS: The pretreatment 
      median serum CA 125 level was 183 U/mL (range, 6.5-5440.0 U/mL) in patients with 
      PFTC. In a univariate Cox regression model, tumor stage and serum CA 125 level 
      were associated significantly with shortened disease free survival (P = 0.006 and 
      P < 0.001, respectively) and with overall survival (P = 0.03 and P = 0. 001, 
      respectively). Lymph node involvement, tumor grade, and patient age were not 
      associated with the length of survival. A multivariate Cox regression model 
      showed that pretreatment the serum CA 125 level was a prognostic factor of 
      disease free and overall survival, independent of tumor stage (P = 0.005 and P = 
      0.01, respectively). The pretreatment serum CA 125 level was correlated with 
      tumor stage (P < 0.001) but not with lymph node involvement (P = 0.8), histologic 
      grade (P = 0.3), or patient age (P = 0.2). The serum CA 125 level during 
      chemotherapy was correlated significantly with Gynecologic Oncology Group 
      response criteria to chemotherapy (P = 0. 001). During the follow-up of patients, 
      serum CA 125 levels reached sensitivity, specificity, positive predictive value, 
      and negative predictive value of 92%, 90%, 67%, and 98%, respectively, for 
      differentiating between no evidence of disease and the presence of recurrent 
      disease. In 90% of the patients, an increase of serum CA 125 level preceded the 
      clinical or radiologic diagnosis of recurrent disease with a median lead time of 
      3 months (range, 0.5-7.0 months). CONCLUSIONS: This is the largest study to date 
      with respect to serum CA 125 levels in patients with PFTC. The current data 
      indicate that the pretreatment serum CA 125 level is an additional independent 
      prognostic factor of disease free and overall survival in patients with PFTC. The 
      serum CA 125 level adequately defines the response to chemotherapy and displays 
      good sensitivity and specificity characteristics during the follow-up of patients 
      with PFTC.
FAU - Hefler, L A
AU  - Hefler LA
AD  - Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, 
      Texas 77030, USA. l_hefler@hotmail.com
FAU - Rosen, A C
AU  - Rosen AC
FAU - Graf, A H
AU  - Graf AH
FAU - Lahousen, M
AU  - Lahousen M
FAU - Klein, M
AU  - Klein M
FAU - Leodolter, S
AU  - Leodolter S
FAU - Reinthaller, A
AU  - Reinthaller A
FAU - Kainz, C
AU  - Kainz C
FAU - Tempfer, C B
AU  - Tempfer CB
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-125 Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - CA-125 Antigen/*analysis
MH  - Fallopian Tube Neoplasms/*immunology/pathology/surgery
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Survival Analysis
EDAT- 2000/10/03 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/10/03 11:00
PHST- 2000/10/03 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/10/03 11:00 [entrez]
AID - 10.1002/1097-0142(20001001)89:7<1555::AID-CNCR20>3.0.CO;2-J [pii]
AID - 10.1002/1097-0142(20001001)89:7<1555::aid-cncr20>3.0.co;2-j [doi]
PST - ppublish
SO  - Cancer. 2000 Oct 1;89(7):1555-60. doi: 
      10.1002/1097-0142(20001001)89:7<1555::aid-cncr20>3.0.co;2-j.